The U.S.
Medical researchers are fundamentally rethinking how clinicians reach aggressive cancers hiding behind the human body’s most formidable biological defenses. While pharmaceutical developers introduce precision pills designed to intercept mutated proteins inside tumor cells, surgical specialists and clinical investigators are simultaneously pursuing mechanical and acoustic strategies to deliver those therapies directly to historically unreachable regions of the central nervous system and abdomen.
Targeting Pancreatic Cancer With Rasonque
For patients facing metastatic pancreatic adenocarcinoma — the most prevalent form of pancreatic cancer — treatment options have historically relied on broad systemic chemotherapies that attack all actively dividing cells. That standard is shifting following the U.S. Food and Drug Administration’s approval of Revolution Medicines’ targeted drug, known generically as daraxonrasib and branded as Rasonque.
Designed as a once-daily pill, the medication blocks several forms of the RAS protein that drive tumor cell growth. According to data from a study of 500 adults with previously treated metastatic pancreatic adenocarcinoma, the drug improved the rate of overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
The therapy targets proteins in the RAS GTPase family, operating against the broader G12 group of KRAS gene changes, which include G12D, G12V, G12R, and G12C mutations. Clinical guidance notes that the drug serves as a treatment option for adults who have already undergone at least one other systemic treatment or who cannot tolerate combination chemotherapy.
Expanding Precision Therapies Across Specific Genetic Mutations
Beyond RAS-driven tumors, therapeutic developments target smaller patient populations defined by specific molecular alterations. A small subset of pancreatic cancers carry changes in the BRAF gene, specifically the BRAFV600E mutation, which can be treated using a combination of dabrafenib and trametinib taken as twice-daily pills. Other targeted pathways include NTRK gene fusions addressed by larotrectinib and entrectinib, and RET gene fusion mutations treated with selpercatinib.
Unlike traditional chemotherapy, which affects both healthy and malignant tissue, these precision agents interfere with specific molecules involved in cancer cell growth and survival. However, they carry distinct side-effect profiles ranging from skin and gastrointestinal issues to abnormal liver function test values, requiring close clinical monitoring by medical oncologists.
Using Soundwaves to Breach the Blood-Brain Barrier
While molecular therapies address abdominal malignancies, researchers attacking pediatric and adult brain cancers face an entirely different obstacle: the blood-brain barrier. This natural defense perimeter protects the central nervous system from pathogens in the bloodstream, but it also blocks life-saving medications from reaching tumors such as diffuse midline glioma, which spreads as individual cells rather than identifiable masses.
To overcome this barrier, Cheng-Chia “Fred” Wu, an assistant professor at the Fralin Biomedical Research Institute at VTC and a collaborator at the Children’s National Brain Tumor Institute, is advancing the use of focused ultrasound combined with microbubbles.
“These microbubbles float through the bloodstream and when they reach the area where the soundwave meets, the sound essentially causes the bubbles to dance to the rhythm of the beat. The bubbles grow and shrink in a rhythmic fashion, and that rhythmic pumping can create a temporary opening of the blood-brain barrier.”
Cheng-Chia “Fred” Wu, assistant professor at the Fralin Biomedical Research Institute at VTC
This non-invasive approach permits therapeutic compounds to reach the brainstem, a sensitive region regulating swallowing, heart rate, and breathing. According to Wu, solving delivery challenges could revive clinical trial candidates that previously failed due to poor barrier penetration.
Collaborative Engineering
At the same time, hardware developers and veterinary researchers are laying groundwork for human clinical translation. Canine clinical trials conducted by John Rossmeisl at the Virginia-Maryland College of Veterinary Medicine inform human studies, while engineering teams collaborate to build novel ultrasound hardware designed specifically for oncology treatment environments.
As regulatory approvals for targeted pills expand alongside engineering advances in focused ultrasound, oncologists gain increasingly diverse tools to confront cancers once considered nearly untreatable.
